Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-Derived Stem Cells for Benign Prostatic Hyperplasia
NCT02961114Phase 2Withdrawn
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous adipose-derived stromal vascular fraction in benign prostatic hyperplasia (BPH). Planned start Nov 2019; status: withdrawn.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02961114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961114.